Walmart Shares Plunge Amid Disappointing U.S. Sales Growth and Drug Price Regulations
Walmart shares experienced a significant drop on Thursday, 6%, following disappointing U.S. sales growth and impacts from Medicaid drug price regulations. Despite using up to $3 billion of expected tariff refunds to mitigate price increases, analysts suggest the stock remains undervalued. Walmart's guidance and recent guidance were seen as lacking, with expectations that the company will struggle to recover beyond this week's data. The retail giant's price adjustments are helping boost sales, but lower-income consumers continue to reduce spending due to higher energy costs.